The spread of coronavirus (COVID-19) has turned into a global pandemic with alarming speed, prompting many to have questions about the stability of global medical product supply chains. Many low- and middle-income countries may face greater risk of medical product shortages as a result of COVID-19, and the pandemic may also exacerbate the ongoing problem of substandard and falsified medicines.
Substandard and falsified medical products (including medicines, vaccines, biologics, and diagnostics) represent a significant and growing threat to human health. Substandard medical products result from errors, corruption, negligence, or poor practice in manufacturing, procurement, regulation, transportation, or storage. By contrast, falsified products result from criminal fraud. Although substandard and falsified medical products have been traded for many centuries, in the last few decades the problem has grown with the increased complexity of the global pharmaceutical economy and internet sales.
Declaración de Oxford y su llamado a la acción para acceso global a productos médicos de calidad garantizada
Los productos médicos de calidad inferior y falsificados (especialmente los medicamentos, las vacunas, los productos biológicos y los diagnósticos) (1) representan una amenaza significativa y creciente para la salud humana. Los medicamentos y productos médicos de calidad inferior son el resultado de errores, corrupción, negligencia o malas prácticas de fabricación, adquisición, regulación, transporte o almacenaje. En cambio, los productos falsificados son el resultado de un fraude criminal.
The global prevalence of diabetes mellitus is increasing alarmingly. However, the quality of vital medicines and medical products used to treat and monitor diabetes remains uncertain but of potential great public health significance. Here, we review the available evidence on the quality of antidiabetic medicines and supplies for self-monitoring of blood glucose (SMBG) and discuss their potential impact for the patients and society.
Substandard and falsified medications pose significant risks to global health. Nearly one in five antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed the health and economic impact of substandard and falsified antimalarials on children under five in Nigeria, where malaria is endemic and poor-quality medications are commonplace.
Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs.
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-and middle-income countries
The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contribute to estimating this risk in the private sector in LMICs, we assessed the quality assurance system of a convenient sample of local private pharmaceutical distributors.
Artemisinin-based combination therapies are the frontline treatment of Plasmodium falciparum malaria.
Quality assurance of medicines supplied to low income and middle-income countries: poor products in shiny boxes?
In today's context of globalisation of pharmaceutical production and distribution, international and national procurement agencies play a de facto key role in defining the quality of medicines available in sub-Saharan Africa.